Tango Therapeutics, Inc.

Tango Therapeutics, Inc. (Nasdaq: TNGX) is a clinical-stage biopharmaceutical company focused on precision oncology, specifically the discovery and development of drugs that exploit cancer cell vulnerabilities through synthetic lethality. The company became publicly traded in 2021 via a merger with BCTG Acquisition Corp., a SPAC sponsored by Baker Brothers Advisors that completed its IPO in 2020. Now operating as a fully reporting public company, Tango filed an 8-K with the SEC on August 6, 2026, under accession number 0001193125-26-338480. Sign up at SpacDesk for full filing history, deal analytics, and real-time SPAC data on TNGX and hundreds of other de-SPAC companies.